UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset

Neuropharmacology

Volumn 82, Issue , 2014, Pages 76-87

  Huot, Philippe ^a,b   Johnston, Tom H ^a   Lewis, Katie D ^c   Koprich, James B ^a   Reyes, M Gabriela ^a   Fox, Susan H ^a,b   Piggott, Matthew J ^c   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Dyskinesia; l DOPA; MPTP; ON time; Parkinson's disease; UWA 121

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; ANTIPARKINSON AGENT; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; METHYLAMINE; N-METHYL-1-CYCLOPROPYL-1-PIPERONYLMETHYLAMINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ANIMAL BEHAVIOR; CALLITHRIX; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; DYSKINESIA; FEMALE; MENTAL DISEASE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; SEVERITY OF ILLNESS INDEX; SPRAGUE DAWLEY RAT; SYNTHESIS; TIME;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENZODIOXOLES; CALLITHRIX; DOPAMINE UPTAKE INHIBITORS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MENTAL DISORDERS; METHYLAMINES; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84898612912     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.01.012     Document Type: Article

References (49)

1. K. Ando, S. Obayashi, Y. Nagai, A. Oh-Nishi, T. Minamimoto, M. Higuchi, T. Inoue, T. Itoh, and T. Suhara PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease PLoS One 7 2012 e46371
2. R. Arai, N. Karasawa, M. Geffard, and I. Nagatsu L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study Neurosci. Lett. 195 1995 195 198
3. R. Arai, N. Karasawa, M. Geffard, T. Nagatsu, and I. Nagatsu Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase Brain Res. 667 1994 295 299
4. R. Arai, N. Karasawa, and I. Nagatsu Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study Brain Res. 706 1996 177 179
5. W. Bara-Jimenez, T. Dimitrova, A. Sherzai, A. Favit, M.M. Mouradian, and T.N. Chase Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease Mov. Disord. 19 2004 1183 1186 (Pubitemid 39429959)
6. P. Bedard, J.D. Parkes, and C.D. Marsden Nomifensine in Parkinson's disease Br. J. Clin. Pharmacol. 4 Suppl. 2 1977 187S 190S (Pubitemid 8184516)
7. B. Berger In vitro uptake of dopamine in serotoninergic nerve terminals: a fluorescence histochemical study on vibratome sections of the rat cerebral cortex Adv. Biochem. Psychopharmacol. 19 1978 405 408
8. B. Berger, and J. Glowinski Dopamine uptake in serotoninergic terminals in vitro: a valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures Brain Res. 147 1978 29 45 (Pubitemid 8318732)
9. D.L. Bourdet, P.R. Tsuruda, G.P. Obedencio, and J.A. Smith Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat J. Pharmacol. Exp. Ther. 341 2012 137 145
10. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
11. S. Fahn The history of dopamine and levodopa in the treatment of Parkinson's disease Mov. Disord. 23 Suppl. 3 2008 S497 S508
12. P.O. Fernagut, Q. Li, S. Dovero, P. Chan, T. Wu, P. Ravenscroft, M. Hill, Z. Chen, and E. Bezard Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys PLoS One 5 2010 e14053
13. S.H. Fox, A.E. Lang, and J.M. Brotchie Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure Mov. Disord. 21 2006 1578 1594 (Pubitemid 44742184)
14. S.H. Fox, N. Visanji, G. Reyes, P. Huot, J. Gomez-Ramirez, T. Johnston, and J.M. Brotchie Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease Can. J. Neurol. Sci. 37 2010 86 95
15. S.H. Fox, N.P. Visanji, T.H. Johnston, J. Gomez-Ramirez, V. Voon, and J.M. Brotchie Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease Arch. Neurol. 63 2006 1343 1344 (Pubitemid 44379848)
16. M.N. Gandy, M. McIldowie, K. Lewis, A.M. Wasik, D. Salomonczyk, K. Wagg, Z.A. Millar, D. Tindiglia, P. Huot, T. Johnston, S. Thiele, B. Nguyen, N.M. Barnes, J.M. Brotchie, M.T. Martin-Iverson, J. Nash, J. Gordon, and M.J. Piggott Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity Med. Chem. Commun. 1 2010 287 293
17. B. Giros, S. el Mestikawy, N. Godinot, K. Zheng, H. Han, T. Yang-Feng, and M.G. Caron Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter Mol. Pharmacol. 42 1992 383 390 (Pubitemid 23024654)
18. J. Gomez-Ramirez, T.H. Johnston, N.P. Visanji, S.H. Fox, and J.M. Brotchie Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov. Disord. 21 2006 839 846 (Pubitemid 44028305)
19. M.J. Hansard, L.A. Smith, M.J. Jackson, S.C. Cheetham, and P. Jenner Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates J. Pharmacol. Exp. Ther. 303 2002 952 958 (Pubitemid 35424376)
20. R.A. Hauser, L. Salin, N. Juhel, and V.L. Konyago Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease Mov. Disord. 22 2007 359 365 (Pubitemid 46569690)
21. M.A. Hely, J.G. Morris, W.G. Reid, and R. Trafficante Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years Mov. Disord. 20 2005 190 199 (Pubitemid 40361122)
22. O. Hornykiewicz, and S.J. Kish Biochemical pathophysiology of Parkinson's disease Adv. Neurol. 45 1987 19 34
23. P. Huot, T.H. Johnston, M.N. Gandy, M.G. Reyes, S.H. Fox, M.J. Piggott, and J.M. Brotchie The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset PLoS One 7 2012 e45587
24. P. Huot, T.H. Johnston, K.D. Lewis, J.B. Koprich, M.G. Reyes, S.H. Fox, M.J. Piggott, and J.M. Brotchie Characterization of 3,4- Methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time J. Neurosci. 31 2011 7190 7198
25. P. Huot, T.H. Johnston, L. Winkelmolen, S.H. Fox, and J.M. Brotchie 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA Neurobiol. Aging 33 194 2012 e195-115
26. P. Jenner, N.M. Rupniak, S. Rose, E. Kelly, G. Kilpatrick, A. Lees, and C.D. Marsden 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset Neurosci. Lett. 50 1984 85 90 (Pubitemid 14074930)
27. T.H. Johnston, P. Huot, S.H. Fox, J.D. Wakefield, K.A. Sykes, W.P. Bartolini, G.T. Milne, J.P. Pearson, and J.M. Brotchie Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease J. Pharmacol. Exp. Ther. 336 2011 423 430
28. T.H. Johnston, Z. Millar, P. Huot, K. Wagg, S. Thiele, D. Salomonczyk, C.J. Yong-Kee, M.N. Gandy, M. McIldowie, K.D. Lewis, J. Gomez-Ramirez, J. Lee, S.H. Fox, M. Martin-Iverson, J.E. Nash, M.J. Piggott, and J.M. Brotchie A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates FASEB J. 26 2012 2154 2163
29. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the folin phenol reagent J. Biol. Chem. 193 1951 265 275
30. M. Mantovani, D.J. Dooley, A. Weyerbrock, R. Jackisch, and T.J. Feuerstein Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes Br. J. Pharmacol. 158 2009 1848 1856
31. C.D. Marsden The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture Neurology 32 1982 514 539 (Pubitemid 12161356)
32. R.A. Matthews Symptomatic treatment of chronic encephalitis with benzedrine sulphate Am. J. Med. Sci. 195 1938 448 451
33. D.E. Nichols, A.J. Hoffman, R.A. Oberlender, P. Jacob 3rd, and A.T. Shulgin Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class J. Med. Chem. 29 1986 2009 2015 (Pubitemid 16030310)
34. J.G. Nutt, J.H. Carter, and N.E. Carlson Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial Arch. Neurol. 64 2007 319 323 (Pubitemid 46425684)
35. J.G. Nutt, J.H. Carter, and G.J. Sexton The dopamine transporter: importance in Parkinson's disease Ann. Neurol. 55 2004 766 773 (Pubitemid 38702571)
36. Parkinson Study Group Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson study group Ann. Neurol. 42 1997 747 755
37. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study Arch. Neurol. 62 2005 241 248
38. R.K. Pearce, M. Jackson, L. Smith, P. Jenner, and C.D. Marsden Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus) Mov. Disord. 10 1995 731 740
39. D.P. Penney, J.M. Powers, M. Frank, C. Willis, and C. Churukian Analysis and testing of biological stains-the Biological Stain Commission Procedures Biotech. Histochem. 77 2002 237 275 (Pubitemid 36124196)
40. O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, F. Stocchi, and E. Tolosa Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given once daily, study): a randomised, double-blind, parallel-group trial Lancet 365 2005 947 954 (Pubitemid 41071428)
41. O. Rascol, W. Poewe, A. Lees, M. Aristin, L. Salin, N. Juhel, L. Waldhauser, and T. Schindler Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study Arch. Neurol. 65 2008 577 583 (Pubitemid 351679649)
42. U.K. Rinne, J.P. Larsen, A. Siden, and J. Worm-Petersen Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group Neurology 51 1998 1309 1314 (Pubitemid 28520549)
43. J.M. Savola, M. Hill, M. Engstrom, H. Merivuori, S. Wurster, S.G. McGuire, S.H. Fox, A.R. Crossman, and J.M. Brotchie Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Mov. Disord. 18 2003 872 883 (Pubitemid 37021161)
44. P. Solomon, R.S. Mitchell, and M. Prinzmetal The use of benzedrine sulfate in postencephalitic Parkinson's disease JAMA 108 1937 1765 1770
45. R. Talati, K. Reinhart, W. Baker, C.M. White, and C.I. Coleman Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors Park. Relat. Disord. 15 2009 500 505
46. P.F. Teychenne, D.M. Park, L.J. Findley, F.C. Rose, and D.B. Calne Nomifensine in parkinsonism J. Neurol. Neurosurg. Psychiatry 39 1976 1219 1221 (Pubitemid 8022983)
47. D.A. van de Vijver, R.A. Roos, P.A. Jansen, A.J. Porsius, and A. de Boer Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa Br. J. Clin. Pharmacol. 54 2002 168 170 (Pubitemid 35024940)
48. N.P. Visanji, R.M. de Bie, T.H. Johnston, A.C. McCreary, J.M. Brotchie, and S.H. Fox The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov. Disord. 23 2008 1922 1925
49. N.P. Visanji, J. Gomez-Ramirez, T.H. Johnston, D. Pires, V. Voon, J.M. Brotchie, and S.H. Fox Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov. Disord. 21 2006 1879 1891 (Pubitemid 44848934)